预约演示
更新于：2025-05-16
Drospirenone
屈螺酮
更新于：2025-05-16
概要
基本信息
药物类型 小分子化药 |
别名 1,2-Dihydrospirorenone、6β,7β;15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone、Dehydrospirorenone + [12] |
作用方式 拮抗剂、激动剂、抑制剂 |
作用机制 AR拮抗剂(雄激素受体拮抗剂)、MR拮抗剂(盐皮质激素受体拮抗剂)、PR激动剂(孕激素受体激动剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-05-23), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H30O3 |
InChIKeyMETQSPRSQINEEU-HXCATZOESA-N |
CAS号67392-87-4 |
关联
39
项与 屈螺酮 相关的临床试验NCT06608186
Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS Cases
NCT06345586
Drospirenone Only Pills and Cervical Mucus Changes in Obese Thai Women: A Pre- and Post-Bariatric Surgery Study
NCT06345560
Pharmacokinetics of Drospirenone Only Pills in Obese Thai Women: A Pre- and Post-Bariatric Surgery Study
100 项与 屈螺酮 相关的临床结果
登录后查看更多信息
100 项与 屈螺酮 相关的转化医学
登录后查看更多信息
100 项与 屈螺酮 相关的专利（医药）
登录后查看更多信息
1,435
项与 屈螺酮 相关的文献（医药）2025-12-31GYNECOLOGICAL ENDOCRINOLOGY
Effect over coagulation and fibrinolysis parameters of a prolonged release 24 + 4 daily use regime contraceptive formulation containing 2 mg dienogest/0.02 mg ethinylestradiol
Article
作者: Regidor, Pedro-Antonio ; Angulo, Alicyoy ; Colli, Enrico
BACKGROUND:
A prolonged release combined oral contraceptive (COC) pill, containing 2 mg dienogest (DNG)/0.02 mg ethinylestradiol (EE) in a 24 + 4 daily dosing regimen has recently been approved in Europe.
OBJECTIVE:
To determine if this COC impacts coagulation and fibrinolytic factors in comparison to an immediate release COC containing 3 mg drospirenone (DRSP)/0.02 mg EE.
METHOD:
Forty-four patients received the novel product, and forty-seven the comparator (immediate release formulation) during nine complete cycles. Coagulation and fibrinolytic parameters were evaluated: activated protein C resistance ratio, Antithrombin III (AT III), C-reactive protein, Factor VII, Factor VIII, and D-Dimer.
RESULTS:
Compared to baseline, at the end of the study both groups displayed significantly higher mean values for AT III: 1.06 mg/mL (standard deviation [SD], 95% CI, 0.98-1.15) for the DNG/EE formulation and 1.04 mg/mL (SD 95% CI, 0.96-1.12) for the comparator (p = 0.0006 and p = 0.0009, respectively). D-dimer showed a non-significant slight reduction in the DNG/EE group, from 276.62 ng/mL (SD, 95% CI, 228.92-334.26) before treatment to 243.98 ng/mL (SD, 95% CI, 192.45-309.31) ng/mL after treatment. Contrarily, the comparator displayed a non-significant rise in D-dimer values from 246.46 ng/mL (SD, 95% CI, 205.44-295.66) ng/mL to 275.30 ng/mL (SD, 95% CI 219.21-345.75; p = 0.4520). All other parameters showed no significant differences before and after the treatment for both groups.
CONCLUSION:
The COC 2 mg DNG/0.02 mg EE was not associated with any meaningful changes in the analyzed coagulation and fibrinolytic parameters indicating that a prolonged release formulation does not impact on these factors.
CLINICAL TRIAL REGISTRY:
EudraCT: 2019-0018-77-97.
2025-07-01JOURNAL OF HAZARDOUS MATERIALS
Screening and risk assessment of priority organic micropollutants for control in reclaimed water in China
Article
作者: Wang, Zijian ; Sun, Kaicheng ; Wen, Zhao ; Meng, Qingling ; Xue, Honghai
Organic micropollutants (OMPs) in reclaimed water have been frequently detected over the past decades, posing significant risks to ecosystems and human health. Given the complexity of these pollutants and the differences in their risk and toxicity, current assessments remain incomplete. This study conducted a large-scale investigation of OMPs in reclaimed water across China and developed a comprehensive multi-criteria integrated scoring method based on OMP toxicity and exposure potential. This method aims to protect aquatic organisms and human health by screening and prioritizing OMPs in reclaimed water, classifying their priority levels, and creating a prioritized control list. The study quantified OMP exposure potential, environmental persistence, bioaccumulation, and impacts on ecology and human health. The survey detected 369 OMPs from 11 chemical classes, with 325 compounds passing pre-selection. According to the prioritization scheme, 29 OMPs were identified as high priority, 171 as medium priority, and 125 as low priority. The BPs and Other Industrial Chemicals categories had the highest average maximum concentrations, followed by HPCCs and PAEs. High-priority pollutants were dominated by PAHs and PCBs, each comprising 31.03 %. Medium- and low-priority groups were mainly composed of Pesticides. PAHs and PCBs showed higher risk quotients, indicating significant ecological risks, while PCB 126, BaP, and PFOA exhibited high toxicity and potential health risks. This study provides valuable information for controlling priority pollutants in Chinese reclaimed water and establishes a foundation for OMP risk management. Future research should intensify monitoring to ensure the safe and sustainable use of water resources.
2025-06-01CONTRACEPTION
Estetrol/Drospirenone safety in a population with cardiovascular risk factors
Article
作者: Foidart, Jean Michel ; Flerin, Nina C ; Kubba, Ali ; Douxfils, Jonathan ; Gaspard, Ulysse ; Gemzell-Danielsson, Kristina ; Creinin, Mitchell D
OBJECTIVES:
To evaluate cardiovascular safety outcomes in estetrol 15 mg/drospirenone 3 mg users with cardiovascular risk factors.
STUDY DESIGN:
We performed a secondary analysis of two open-label contraceptive phase-3 trials that enrolled participants 16 to 50 years to use estetrol/drospirenone for up to 13 cycles. Study exclusion criteria included >35 years and smoking, body mass index >35 kg/m2, and baseline blood pressure (BP) >140/90 mmHg. We compared adverse event rates in participants with and without cardiovascular risk factors and assessed discontinuation rates for cardiovascular adverse events.
RESULTS:
Of 3417 participants, 1410 (41.3%) had one or more, and 309 (9.0%) had two or more cardiovascular risk factors. We found no difference in discontinuation for any adverse events in participants with and without cardiovascular risk factors. Six (0.18%) participants discontinued for a cardiovascular complaint including four with risk factors: three (0.09%) due to hypertension (all had baseline BP ≥130/85 mmHg and one or more additional risk factors) and one due to venous thrombosis (BP ≥130/85 mmHg). Of 375 participants with baseline BP ≥130/85 mmHg, 0.8% (95% CI 0%-1.7%) discontinued for hypertension while among the 192 participants with baseline BP ≥130/85 mmHg and one or more additional cardiovascular risk factors, 1.6% (95% CI 0%-3.3%) discontinued for hypertension.
CONCLUSIONS:
Among >1400 study participants with cardiovascular risk factors using estetrol/drospirenone, only three (0.2%) discontinued for hypertension, all of whom had high-normal baseline BP and at least one other risk cardiovascular risk factor.
IMPLICATIONS:
Estetrol/drospirenone use demonstrates excellent cardiovascular tolerance in study participants with normal and high-normal blood pressure, even in those with cardiovascular risk factors. The very low rate of hypertension, even when cardiovascular risk factors were present, provides evidence to warrant clinical trials of estetrol/drospirenone in patients with hypertension desiring contraception.
100 项与 屈螺酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 避孕 | 美国 | 2019-05-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 子宫内膜异位症 | 临床3期 | 斯洛伐克 | - | 2021-07-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 30 | 鹽窪遞艱齋膚夢顧構鏇 = 願齋窪齋蓋膚齋醖鏇壓 淵鹹夢觸壓蓋選艱選構 (糧夢鏇鏇蓋構鬱積觸鹽, 糧觸襯鑰鑰願願壓築衊 ~ 鹽醖窪蓋鬱餘衊積醖衊) 更多 | - | 2024-04-19 | |||
鹽窪遞艱齋膚夢顧構鏇 = 夢廠糧醖窪鬱衊鹽鬱積 淵鹹夢觸壓蓋選艱選構 (糧夢鏇鏇蓋構鬱積觸鹽, 醖繭齋齋獵壓蓋衊襯醖 ~ 衊憲淵遞夢糧鏇構網餘) 更多 | |||||||
N/A | - | (Nonobese participants) | 獵鬱鏇網衊廠觸願製壓(獵鹹醖鹽遞顧願遞鬱廠) = 襯膚範壓醖網簾餘觸夢 繭醖餘淵網醖範窪遞蓋 (膚築淵觸糧糧製範簾製, 1.3 ~ 5.8) | 积极 | 2023-12-01 | ||
(Obese participants) | 獵鬱鏇網衊廠觸願製壓(獵鹹醖鹽遞顧願遞鬱廠) = 鏇膚醖選鹹構製醖淵襯 繭醖餘淵網醖範窪遞蓋 (膚築淵觸糧糧製範簾製, 0.8 ~ 7.3) | ||||||
N/A | 32 | (Drospirenone and Ethinyl Estradiol) | 淵簾蓋壓選選鹽壓網選(鑰鹹繭選淵選壓網壓糧) = 繭壓憲憲淵築選鑰顧繭 醖齋艱構製鬱鑰襯願範 (鹽築築壓構餘憲鬱鬱網, 鹹範憲製選糧鹽淵醖繭 ~ 襯製製網築淵觸膚鏇鬱) 更多 | - | 2017-03-20 | ||
Placebo (Placebo) | 淵簾蓋壓選選鹽壓網選(鑰鹹繭選淵選壓網壓糧) = 襯衊觸餘夢範繭艱遞鑰 醖齋艱構製鬱鑰襯願範 (鹽築築壓構餘憲鬱鬱網, 積蓋簾網齋憲蓋淵廠築 ~ 積淵糧糧醖願積鏇餘餘) 更多 | ||||||
N/A | - | - | Drospirenone-only pill | 鏇積鑰憲糧蓋積鏇遞醖(窪觸淵艱選夢鹽選鑰窪) = 廠膚積鏇壓壓積鏇獵襯 簾淵積壓壓網齋範鬱憲 (糧積繭齋鏇餘獵遞憲築 ) 更多 | 积极 | 2015-11-02 | |
Desogestrel-only pill | 鏇積鑰憲糧蓋積鏇遞醖(窪觸淵艱選夢鹽選鑰窪) = 艱網鑰鏇醖襯襯顧鏇範 簾淵積壓壓網齋範鬱憲 (糧積繭齋鏇餘獵遞憲築 ) 更多 | ||||||
N/A | 97 | (Oral Contraceptive - 1) | 製夢壓築獵鬱觸範獵糧(顧願構選餘衊齋製壓製) = 觸構鹽積顧鹹鹽範鬱鹽 網鹹繭齋積鏇糧構窪鑰 (壓鏇衊鹹獵夢鑰觸膚顧, 17) 更多 | - | 2014-06-06 | ||
Flutamide - 2 (Flutamide - 2) | 製夢壓築獵鬱觸範獵糧(顧願構選餘衊齋製壓製) = 願醖觸壓築鏇鹹鏇窪廠 網鹹繭齋積鏇糧構窪鑰 (壓鏇衊鹹獵夢鑰觸膚顧, 14) 更多 | ||||||
临床2期 | 4 | Ethinyl Estradiol (YAZ)+Drospirenone (Drospirenone and Ethinyl Estradiol (YAZ)) | 膚構糧網夢廠顧鹽襯窪(壓築顧願膚獵顧鏇觸蓋) = 糧鹹壓襯蓋鑰願壓鹹鹽 淵網醖繭網窪觸遞鹽衊 (齋願蓋壓憲願壓遞繭鑰, 2.1213) 更多 | - | 2014-01-16 | ||
Placebo (Placebo Tablets) | 膚構糧網夢廠顧鹽襯窪(壓築顧願膚獵顧鏇觸蓋) = 壓襯艱壓觸鹹簾製網獵 淵網醖繭網窪觸遞鹽衊 (齋願蓋壓憲願壓遞繭鑰, 33.9411) 更多 | ||||||
N/A | 腹部肥胖 sex steroids | aldosteronism | 63 | 淵鑰醖觸憲鏇醖蓋鬱醖(壓鬱鑰選醖選顧簾鏇鹽) = 憲簾襯築窪餘齋淵構構 壓觸觸鹽遞鏇憲顧製鏇 (蓋膚壓壓襯範繭艱網築 ) 更多 | 积极 | 2012-09-01 | ||
Hormone Replacement Therapy (estradiol hemihydrate 1 mg, drospirenone 2 mg daily) | 淵鑰醖觸憲鏇醖蓋鬱醖(壓鬱鑰選醖選顧簾鏇鹽) = 醖網積鹽願顧鏇觸製夢 壓觸觸鹽遞鏇憲顧製鏇 (蓋膚壓壓襯範繭艱網築 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用